TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07285239: Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

Sponsor: PrECOG, LLC. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 500 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT07285239 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07285239 Rescue Dossier →